Evolution Wealth Advisors’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Evolution Wealth Advisors’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.68M	Hold	13,189	–	–	0.17%	54
2025 Q4	$1.61M	Sell	13,189 -149	-1%	-$17.1K	0.16%	55
2025 Q3	$1.34M	Sell	13,338 -96	-0.7%	-$8.65K	0.18%	59
2025 Q2	$1.11M	Sell	13,434 -1,139	-8%	-$90.9K	0.16%	68
2025 Q1	$1.18M	Sell	14,573 -15,545	-52%	-$1.39M	0.2%	60
2024 Q4	$2.71M	Buy	30,118 +5	+0%	+$484	0.45%	40
2024 Q3	$2.98M	Sell	30,113 -210	-0.7%	-$20.6K	0.53%	39
2024 Q2	$2.81M	Buy	30,323 +839	+3%	+$75.2K	0.55%	39
2024 Q1	$2.8M	Buy	29,484 +1,203	+4%	+$112K	0.54%	38
2023 Q4	$2.53M	Buy	28,281 +68	+0.2%	+$5.05K	0.51%	44
2023 Q3	$2.06M	Buy	28,213 +1,965	+7%	+$157K	0.46%	42
2023 Q2	$2.18M	Buy	26,248 +1,054	+4%	+$88.1K	0.48%	39
2023 Q1	$1.92M	Sell	25,194 -973	-4%	-$80.7K	0.46%	40
2022 Q4	$2.17M	Buy	26,167 +1,665	+7%	+$135K	0.55%	38
2022 Q3	$1.94M	Sell	24,502 -898	-4%	-$75.7K	0.53%	32
2022 Q2	$1.89M	Sell	25,400 -27,242	-52%	-$2.04M	0.48%	37
2022 Q1	$4.73M	Buy	52,642 +8,079	+18%	+$746K	0.97%	23
2021 Q4	$4.99K	Sell	44,563 -1,771	-4%	-$214K	0.75%	26
2021 Q3	$5.83M	Buy	46,334 +2,722	+6%	+$351K	1.25%	19
2021 Q2	$5.91M	Buy	43,612 +119	+0.3%	+$15.6K	1.2%	21
2021 Q1	$5.9M	Buy	43,493 +3,422	+9%	+$512K	1.32%	20
2020 Q4	$5.64M	Buy	40,071 +2,608	+7%	+$334K	1.27%	22
2020 Q3	$4.17M	Buy	37,463 +2,326	+7%	+$261K	1.14%	26
2020 Q2	$3.93M	Buy	35,137 +35,015	+28,701%	+$3.45M	1.29%	18
2020 Q1	$9K	Sell	122 -3,343	-96%	-$296K	﹤0.01%	219
2019 Q4	$330K	Buy	3,465 +3,385	+4,231%	+$293K	0.08%	58
2019 Q3	$6K	Buy	+80	New	+$6.65K	﹤0.01%	262

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Evolution Wealth Advisors's XBI Position: Q1 2026 in Review

Evolution Wealth Advisors held its State Street SPDR S&P Biotech ETF (XBI) position steady in Q1 2026 at 13,189 shares worth $1.68M. The position accounts for 0.17% of the portfolio, ranked #54.

Evolution Wealth Advisors first reported a position in XBI in Q3 2019 and has held it in 27 quarters since. The position peaked at $5.91M in Q2 2021. 813 funds tracked by Wall St. Rank hold XBI as of Q1 2026.

Evolution Wealth Advisors held 13,189 shares of State Street SPDR S&P Biotech ETF worth $1.68M as of Q1 2026.
Evolution Wealth Advisors left its State Street SPDR S&P Biotech ETF share count unchanged in Q1 2026.
State Street SPDR S&P Biotech ETF made up 0.17% of Evolution Wealth Advisors's portfolio in Q1 2026, its #54 holding.
Evolution Wealth Advisors first reported a position in State Street SPDR S&P Biotech ETF in Q3 2019 and has held it in 27 quarters since.
Evolution Wealth Advisors's State Street SPDR S&P Biotech ETF position peaked at $5.91M in Q2 2021.
813 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.

Based on Evolution Wealth Advisors's 13F filing for Q1 2026, filed 8 May 2026.